Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV

Phase 2

Terminated

• Conditions: Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV
• Interventions: Biological: Recombinant Human rEGF-P64K/Montanide Vaccine

• Registration Number: NCT00516685
• Lead Sponsor: Bioven Sdn. Bhd.

Brief Summary

The purpose of this study is to determine whether the recombinant human EGF-rP64K/Montanide ISA 51 vaccine is safe, immunogenic and effective in the treatment of stage IIIb/IV non-small-cell lung cancer (NSCLC).

Detailed Description

Not available

Study Timeline

• Study Start: 2007-07
• Study First Submitted: 2007-08-14
• Study First Submitted QC: 2007-08-14
• Study First Posted: 2007-08-15
• Status Verified: 2011-09
• Last Update Submitted: 2011-09-29
• Last Update Posted: 2011-09-30

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 230

Inclusion Criteria

• Patients who have signed the informed consent form.
• Patients who are eighteen years of age or over with histologically or cytologically confirmed NSCLC in advanced stages IIIb or IV, not amenable to any attempt of curative chemo-radiotherapy and/or surgery.
• Patients with measurable lesions, defined as those measurable at least in one dimension (refered to higher diameter) and with a diameter equal or higher 20 mm using conventional techniques (PET, CT scan, MRI, Rx) or equal or higher 10 mm using CT scan.
• Patients who have finished their last cycle of chemotherapy and/or radiotherapy not less than 4 weeks prior to randomization and not more than 8 weeks.
• Female patients of reproductive potential must have negative pregnancy tests. Those female volunteers admitted to the study must be using a reliable means of contraception such as tubal ligation, oral contraceptive or IUD.
• ECOG status 0 to 2.
• Patients with normal organ and bone marrow function, as defined by the parameters in accordance to that provided by the normal lab reference range.
• Patients with no evidence of objective disease progression, 1 month after finishing first line chemotherapy as per RECIST.

Exclusion Criteria

• Patients who are candidates for combined modality treatment.
• Patients who are receiving immunosuppressive therapy including corticosteroids.
• Patients who have received immunotherapy within the previous 3 months.
• Patients who have participated in a clinical study within the previous 30 days.
• Patients who may be allergic to any component of the vaccine.
• Medical reasons considered by the investigators as disqualification from the study such as significant uncontrolled co-morbid disease or potential non-compliance with the protocol.
• Patients bearing brain metastasis from the primary lung tumor.
• Patients bearing a second primary tumor.
• Patients showing progressive disease after finishing first line chemotherapy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Vaccine Group	Recombinant Human rEGF-P64K/Montanide Vaccine	Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.

Primary Outcome Measures

Name	Time	Method
Survival	Two and a half years

Secondary Outcome Measures

Name	Time	Method
Assessment of immunogenecity, safety as well as preliminary assessment of objective response, time of progression and quality of life	Two and a half years

Trial Locations

Locations (1)

Local Institution; 🇲🇾 Kuala Lumpur, Malaysia